Brief Bulletins from the Field Archives - Page 4 of 17

Placebo-controlled trial: The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain

By James La Rossa|2021-08-23T10:20:11-07:00August 23rd, 2021|Brief Bulletins from the Field, We Know Psychiatry|

Background Precise cannabis treatment dosing remains a major challenge, leading to physicians’ reluctance to prescribe medical cannabis. Objective To test the pharmacokinetics, analgesic effect, cognitive performance and safety effects of an innovative medical device that enables the delivery of inhaled therapeutic doses of Δ9-Tetrahydrocannabinol (THC) in patients with chronic pain. [...]

0

Check List for Suicide Risk is Validated

By James La Rossa|2021-11-11T16:56:43-08:00August 16th, 2021|Brief Bulletins from the Field, We Know Psychiatry|

The objective of this research was to develop and evaluate an evidence-based suicide attempt risk checklist [i.e., the Durham Risk Score (DRS)] to aid clinicians in the identification of individuals at risk for attempting suicide in the future. Methods and findings Three prospective cohort studies, including a population-based study from [...]

0

Real Patient Confessions on Reddit: Self Mutilation/Grief After Therapist Dies

By James La Rossa|2021-08-05T08:48:11-07:00August 5th, 2021|Brief Bulletins from the Field, We Know Psychiatry|

I cut myself for the first time today and I feel worse I'm up at 5 am writing this because I can't sleep and anxiety is keeping me up. I'm a 17 year old girl and cut myself with a blade for the first time today. I have cut myself [...]

1

Biogen Withdrew Aduhelm Paper After JAMA Asked for Edits

By James La Rossa|2021-08-03T09:26:20-07:00August 3rd, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

According to well-placed recent reports, Biogen Inc withdrew its paper that analyzed results from the clinical trials of its controversial Alzheimer's drug, Aduhelm, that was submitted to medical journal JAMA. Biogen withdrew the paper as JAMA considered rejecting it unless edits were made, according to the report. (https://bit.ly/3f2zsvf) The U.S. [...]

0

Some Teenagers At Risk Of Self-Harming Can Be Identified A Decade In Advance

By James La Rossa|2021-07-30T04:21:28-07:00July 30th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

There are multiple risk factors for self-harm, including a history of abuse, trauma, physical and mental illness, and bullying. Identifying these factors is a key part of prevention, ensuring that those at risk receive appropriate support as early as possible — but despite this, predicting who may end up engaging [...]

0

FDA Reviewers: Why We Are Against Approval of Aducanumab for Alzheimer’s

By James La Rossa|2021-05-06T09:35:36-07:00May 6th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

Three members of a US Food and Drug Administration (FDA) advisory committee are explaining why they do not support approval of the drug aducanumab (Biogen, Eisai) for the treatment of Alzheimer's disease (AD). G. Caleb Alexander, MD, Scott Emerson, MD, PhD, and Aaron Kesselheim, MD, JD, MPH, all serve on the [...]

0

Novel Drug Offers Rapid Relief From Agitation in Serious Mental Illness

By James La Rossa|2021-05-06T09:36:50-07:00May 6th, 2021|Brief Bulletins from the Field, Featured, We Know Psychiatry|

An investigational, orally dissolving film formulation of dexmedetomidine (BXCL501, BioXcel Therapeutics) may offer rapid relief from acute agitation related to schizophrenia or bipolar disorder (BD), results of two phase 3, randomized, placebo-controlled trials show. Dr Leslie Citrome For both disorders, BXCL501 showed "superiority over placebo" by meeting the primary endpoint of reduction of agitation as [...]

0

An Analytical and Legal Spotlight on Cannabis

By James La Rossa|2021-02-23T09:27:58-08:00February 23rd, 2021|Brief Bulletins from the Field, We Know Psychiatry|

Cannabis sativa has a long history of use both as a textile and as an intoxicant used for medicinal, spiritual, and recreational purposes. California voted to regulate cannabis for medical use in 1996, and in recent years there has been a wave of US states and other countries passing legislation [...]

0

Associations between breast cancer survivorship and adverse mental health outcomes: A matched population-based cohort study in the United Kingdom

By James La Rossa|2021-01-19T12:45:20-08:00January 19th, 2021|Brief Bulletins from the Field, We Know Psychiatry|

SUMMARY In this study, we observed that compared to women with no prior cancer, breast cancer survivors had higher risk of anxiety, depression, sleep problems, sexual dysfunction, fatigue, receipt of opioid analgesics, and pain. Relative risks estimates tended to decrease over time, but anxiety and depression were significantly increased for [...]

0

Suicide Prevention in the COVID-19 Era Transforming Threat Into Opportunity

By James La Rossa|2020-10-20T09:07:02-07:00October 20th, 2020|Brief Bulletins from the Field, We Know Psychiatry|

From: JAMA Psychiatry. Published online October 16, 2020. doi:10.1001/jamapsychiatry.2020.3746 By Christine Moutier, MD Introduction International and US experts on suicide have expressed concerns about the potential the coronavirus disease 2019 (COVID-19) pandemic has to increase the risk of suicide through its effects on a number of well-established suicide risk factors.1,2 Suicide surveillance [...]

0